BidaskClub lowered shares of Kala Pharmaceuticals (NASDAQ:KALA) from a buy rating to a hold rating in a research report sent to investors on Tuesday, BidAskClub reports.

Several other research firms have also weighed in on KALA. ValuEngine lowered Kala Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, December 21st. Zacks Investment Research raised Kala Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, April 3rd. Wedbush set a $51.00 price target on Kala Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, January 16th. HC Wainwright reaffirmed a buy rating and set a $15.00 price target on shares of Kala Pharmaceuticals in a research report on Thursday, December 27th. Finally, Jefferies Financial Group initiated coverage on Kala Pharmaceuticals in a research report on Thursday, March 14th. They set a buy rating and a $15.00 price target on the stock. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $20.58.

NASDAQ:KALA opened at $7.60 on Tuesday. The company has a market cap of $257.51 million, a price-to-earnings ratio of -3.06 and a beta of 1.73. Kala Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $17.39. The company has a current ratio of 10.41, a quick ratio of 10.17 and a debt-to-equity ratio of 0.67.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.23). Research analysts forecast that Kala Pharmaceuticals will post -2.83 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Deutsche Bank AG boosted its stake in shares of Kala Pharmaceuticals by 349.6% during the 4th quarter. Deutsche Bank AG now owns 268,054 shares of the company’s stock worth $1,310,000 after acquiring an additional 208,436 shares during the period. Geode Capital Management LLC boosted its stake in shares of Kala Pharmaceuticals by 79.4% during the 4th quarter. Geode Capital Management LLC now owns 199,935 shares of the company’s stock worth $977,000 after acquiring an additional 88,484 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Kala Pharmaceuticals by 62.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 255,760 shares of the company’s stock worth $1,251,000 after acquiring an additional 98,591 shares during the period. Sofinnova Investments Inc. boosted its stake in shares of Kala Pharmaceuticals by 365.8% during the 4th quarter. Sofinnova Investments Inc. now owns 445,516 shares of the company’s stock worth $2,178,000 after acquiring an additional 349,861 shares during the period. Finally, RA Capital Management LLC boosted its stake in shares of Kala Pharmaceuticals by 114.7% during the 4th quarter. RA Capital Management LLC now owns 4,537,478 shares of the company’s stock worth $22,188,000 after acquiring an additional 2,424,242 shares during the period. 67.20% of the stock is currently owned by hedge funds and other institutional investors.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Article: What is a blue-chip stock?

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.